Johnson & Johnson (NYSE:JNJ) Price Target Raised to $162.00

Johnson & Johnson (NYSE:JNJ) had its target price hoisted by Guggenheim from $156.00 to $162.00 in a research note published on Wednesday,Benzinga reports. They currently have a neutral rating on the stock.

A number of other equities analysts also recently issued reports on the stock. Sanford C. Bernstein raised their price objective on shares of Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 16th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. Wells Fargo & Company lifted their target price on Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 16th. Finally, TD Cowen decreased their price objective on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research note on Thursday, July 18th. Seven equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average price target of $175.00.

Johnson & Johnson Trading Down 0.7 %

Shares of JNJ stock opened at $155.62 on Wednesday. The stock has a market capitalization of $374.67 billion, a P/E ratio of 22.52, a P/E/G ratio of 2.80 and a beta of 0.53. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The firm’s 50 day moving average is $162.61 and its 200 day moving average is $155.81. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $168.85.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping the consensus estimate of $2.21 by $0.21. The company had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. Johnson & Johnson’s revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.66 earnings per share. Research analysts expect that Johnson & Johnson will post 9.94 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be paid a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.19%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s payout ratio is currently 71.78%.

Insider Activity

In related news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares in the company, valued at approximately $3,131,683.38. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.16% of the company’s stock.

Institutional Investors Weigh In On Johnson & Johnson

Several large investors have recently bought and sold shares of JNJ. LPL Financial LLC grew its position in Johnson & Johnson by 10.2% in the third quarter. LPL Financial LLC now owns 3,714,260 shares of the company’s stock worth $601,933,000 after acquiring an additional 344,641 shares in the last quarter. German American Bancorp Inc. boosted its holdings in shares of Johnson & Johnson by 7.7% in the 3rd quarter. German American Bancorp Inc. now owns 50,275 shares of the company’s stock worth $8,148,000 after purchasing an additional 3,612 shares during the period. America First Investment Advisors LLC increased its position in shares of Johnson & Johnson by 2.0% during the 3rd quarter. America First Investment Advisors LLC now owns 126,437 shares of the company’s stock valued at $20,490,000 after purchasing an additional 2,441 shares during the last quarter. Landscape Capital Management L.L.C. bought a new stake in Johnson & Johnson in the third quarter worth $365,000. Finally, Overbrook Management Corp boosted its stake in Johnson & Johnson by 3.4% during the third quarter. Overbrook Management Corp now owns 6,455 shares of the company’s stock worth $1,046,000 after buying an additional 212 shares during the period. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.